Wednesday, September 19, 2012
GeNeuro SA, of Geneva, launched a Phase IIa study with GNbAC1 , its humanized monoclonal antibody targeting a human endogenous retrovirus, in multiple sclerosis (MS).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.